Cover Image


Combination Inhalers for Upper Airway Diseases

出版商 Greystone Research Associates 商品編碼 337817
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
面向上呼吸道疾病組合吸入藥市場 Combination Inhalers for Upper Airway Diseases
出版日期: 2015年08月24日 內容資訊: 英文

由於可用性,及對許多患者來說上呼吸道疾病相關症狀的管理改善, 組合吸入藥的開發活動及產品普及大幅度增加。組合吸入藥主要以吸入皮質類固醇和支氣管擴張劑的組合構成。這些產品,預測2020年代後半將大幅度增加的2個市場 - 氣喘及慢性阻塞性肺病的市場將取得大幅商業性成功。

本報告提供組合 (並用) 口服吸入藥的市場相關調查、輸送複數藥物的口服吸入器技術、產品的技術課題與發展的市場要素、開發階段的聯合治療吸入藥與市場投入計劃、吸入藥廠商與對其聯盟合作夥伴的經濟、技術、規定要素的影響等相關分析、組合吸入藥的市場資料與預測,及主要企業簡介等彙整,為您概述為以下內容。



  • 上呼吸道治療藥市場
  • 組合吸入藥的治療目標
  • 競爭的治療藥
  • 需求的促進要素
  • 技術要素
  • 競爭情形


  • 全球患者統計
  • 地區市場促進要素
  • 治療需求擴大


  • 乾粉吸入劑 (DPI)
    • DPI處方技術
    • 特徵、參數
    • DPI賦形劑、包裝
  • 定量吸入器 (MDI)
    • MDI設備的選擇標準
    • 可用性的因素
  • 噴霧器


  • Albuterol/Ipratropium (噴霧器)
  • Albuterol/Ipratropium (MDI)
  • Generic Albuterol/Ipratropium Solution
  • Fluticasone/Vilanterol (DPI)
  • Fluticasone/Salmeterol (MDI)
  • Fluticasone/Salmeterol (DPI)
  • Budesonide/Formoterol (MDI)
  • Formoterol/Mometasone (MDI)
  • Umeclidinium/Vilanterol (DPI)


  • 乾粉處方藥
  • 定量處方藥
  • 噴霧器給藥解決方案


  • 氣喘
    • 需求要素
    • 地區性的市場影響要素
  • COPD


  • 法律規章上的課題
  • 患者服藥遵守
  • 處方趨勢
  • 醫療經濟學
  • 地區性的市場影響要素
  • 連網型設備


Product Code: DHJ554F

Analyzing the Growth of Dual Therapy Inhalers

Combination inhalers - oral inhalers containing two drugs that complement the therapeutic actions of one another - have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated - Asthma and COPD - both of which are forecast to grow at impressive rates for the remainder of the decade.

The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

‘The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. The current trend in asthma and COPD inhaler evolution has seen an increase in the incorporation of ergonomic features by device designers aimed at increasing patient receptiveness. Recent inhaler designs have approached the goals of improved usability and patient adherence from a number of distinct directions, including dose preparation technology, dose packaging, novel formulation technology, dosing confirmation, and symptoms monitoring.’

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.

Report Highlights

  • Analyzes the market for combination (dual drug) oral inhalers
  • Assesses oral inhalation device technology for delivering multiple drugs, and evaluates product technology issues and evolving market factors
  • Provides detailed assessments of combination drug inhalers, their growth prospects and market potential
  • Evaluates development-stage dual therapy inhalers and assesses likely market entry timelines
  • Provides market data and forecasts for dual drug oral inhaler products to 2022
  • Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
  • Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Table of Contents

Executive Summary

Orally Inhaled Corticosteroid Market Overview

  • The Upper Respiratory Therapeutics Marketspace
  • Therapeutic Targets for Combination Inhalers
  • Competing Drug Treatments
  • Demand Drivers
  • Technology Factors
  • Competitive Landscape

Asthma Market Risks and Opportunities

  • Global Patient Demographics
  • Regional Market Drivers
  • The Growing Therapeutic Need

Inhaler Technologies for Delivering Combination Therapies

  • Dry Powder Inhalers
    • DPI Formulation Technology
    • Characteristics and Parameters
    • DPI Excipients and Packaging
  • Metered Dose Inhalers
    • MDI Device Selection Criteria
    • Ease-of-Use Factors
  • Nebulizers

Combination Inhalers - Product Analysis, Market Data & Forecasts

  • Albuterol/Ipratropium (Nebulizer)
  • Albuterol/Ipratropium (MDI)
  • Generic Albuterol/Ipratropium Solution
  • Fluticasone/Vilanterol (DPI)
  • Fluticasone/Salmeterol (MDI)
  • Fluticasone/Salmeterol (DPI)
  • Budesonide/Formoterol (MDI)
  • Formoterol/Mometasone (MDI)
  • Umeclidinium/Vilanterol (DPI)

Development-stage Combination Inhalers

  • Dry Powder Formulations
  • Metered Dose Formulations
  • Nebulized Solutions

Therapeutic Market Assessment

  • Asthma
    • Demand Factors
    • Regional Market Factors
  • COPD
    • Demand Factors
    • Regional Market Factors

Market Factors

  • Regulatory Issues
  • Patient Compliance
  • Prescribing Trends
  • Healthcare Economics
  • Regional Market Factors
  • Connected Devices

Market Sector Company Profiles

Back to Top